Max D Wellenstein
Overview
Explore the profile of Max D Wellenstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1675
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hassin O, Sernik M, Seligman A, Vogel F, Wellenstein M, Smollich J, et al.
Proc Natl Acad Sci U S A
. 2023 Dec;
120(52):e2311460120.
PMID: 38127986
The gene is mutated in approximately 30% of all breast cancer cases. Adipocytes and preadipocytes, which constitute a substantial fraction of the stroma of normal mammary tissue and breast tumors,...
2.
Blomberg O, Kos K, Spagnuolo L, Isaeva O, Garner H, Wellenstein M, et al.
Oncoimmunology
. 2023 Apr;
12(1):2201147.
PMID: 37089449
The clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the neoadjuvant and perioperative setting. However, how neoadjuvant ICB...
3.
Yeung J, Florescu M, Zeller P, de Barbanson B, Wellenstein M, van Oudenaarden A
Nat Biotechnol
. 2023 Jan;
41(6):813-823.
PMID: 36593403
Regulation of chromatin states involves the dynamic interplay between different histone modifications to control gene expression. Recent advances have enabled mapping of histone marks in single cells, but most methods...
4.
Zimmerli D, Brambillasca C, Talens F, Bhin J, Linstra R, Romanens L, et al.
Nat Commun
. 2022 Nov;
13(1):6579.
PMID: 36323660
The limited efficacy of immune checkpoint inhibitor treatment in triple-negative breast cancer (TNBC) patients is attributed to sparse or unresponsive tumor-infiltrating lymphocytes, but the mechanisms that lead to a therapy...
5.
Kos K, Salvagno C, Wellenstein M, Aslam M, Meijer D, Hau C, et al.
Oncoimmunology
. 2022 Apr;
11(1):2063225.
PMID: 35481289
While regulatory T cells (T) and macrophages have been recognized as key orchestrators of cancer-associated immunosuppression, their cellular crosstalk within tumors has been poorly characterized. Here, using spontaneous models for...
6.
Kos K, Aslam M, van de Ven R, Wellenstein M, Pieters W, van Weverwijk A, et al.
Cell Rep
. 2022 Mar;
38(9):110447.
PMID: 35235800
Breast cancer is accompanied by systemic immunosuppression, which facilitates metastasis formation, but how this shapes organotropism of metastasis is poorly understood. Here, we investigate the impact of mammary tumorigenesis on...
7.
Prekovic S, Schuurman K, Mayayo-Peralta I, Manjon A, Buijs M, Yavuz S, et al.
Nat Commun
. 2021 Jul;
12(1):4360.
PMID: 34272384
The glucocorticoid receptor (GR) regulates gene expression, governing aspects of homeostasis, but is also involved in cancer. Pharmacological GR activation is frequently used to alleviate therapy-related side-effects. While prior studies...
8.
Duits D, Wellenstein M, de Visser K
Methods Enzymol
. 2020 Feb;
632:133-154.
PMID: 32000893
The progression of cancer is strongly influenced by the crosstalk between cancer cells and immune cells. Immune cells can have both pro- and anti-tumor functions depending on the signals present...
9.
Wellenstein M, Coffelt S, Duits D, van Miltenburg M, Slagter M, de Rink I, et al.
Nature
. 2019 Aug;
572(7770):538-542.
PMID: 31367040
Cancer-associated systemic inflammation is strongly linked to poor disease outcome in patients with cancer. For most human epithelial tumour types, high systemic neutrophil-to-lymphocyte ratios are associated with poor overall survival,...
10.
Wellenstein M, de Visser K
Cancer Cell
. 2019 Jun;
35(6):827-829.
PMID: 31185209
Understanding how tumors escape from immune attack may offer novel therapeutic opportunities. Veglia et al. (2019) demonstrate in Nature that fatty acid transport protein 2 (FATP2) endows neutrophils with immunosuppressive...